These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38602214)

  • 1. [Dupilumab : a new treatment for severe T2 high asthma].
    Louis R; Sabbe M; Bougard N; Frix AN; Schleich F
    Rev Med Liege; 2024 Apr; 79(4):255-259. PubMed ID: 38602214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
    Sabbe M; Schleich F; Janssens P; Louis R
    J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab for the treatment of asthma.
    Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
    Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma.
    Sofia C; Simonetti J; Boccabella C; Bonini M
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab: A Review in Moderate to Severe Asthma.
    Deeks ED
    Drugs; 2019 Nov; 79(17):1885-1895. PubMed ID: 31728838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
    Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
    Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
    Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
    Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
    Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma.
    Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Takada K; Imoto S; Nagase T; Ohta K
    Intern Med; 2024 Jan; 63(2):179-187. PubMed ID: 37225484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
    Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic Asthma.
    Gates J; Hearn A; Mason T; Fernandes M; Green L; Thomson L; Roxas C; Lam J; d'Ancona G; Nanzer AM; Dhariwal J; Jackson DJ
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1794-1800. PubMed ID: 38583517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
    Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
    Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
    Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
    Brusselle G; Quirce S; Papi A; Kuna P; Chipps BE; Hanania NA; Blaiss M; Msihid J; Jacob-Nara JA; Deniz Y; Rowe PJ; Gall R; Ortiz B; Djandji M; Radwan A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):873-884.e11. PubMed ID: 36572184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
    Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
    Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab for the treatment of asthma.
    Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
    Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.